What are the criteria for initiating ezetimibe/rosuvastatin (Repatha) in patients with elevated low‑density lipoprotein cholesterol despite maximally tolerated statin therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Criteria to Initiate Repatha (Evolocumab)

Repatha should be added when LDL-C remains ≥70 mg/dL despite maximally tolerated statin therapy plus ezetimibe in patients with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk. 1, 2

Stepwise Algorithm Before Considering Repatha

You must exhaust the following steps before initiating a PCSK9 inhibitor like Repatha:

Step 1: Maximize Statin Therapy

  • Ensure the patient is on high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) that achieves ≥50% LDL-C reduction 1
  • If the patient cannot tolerate high-intensity statins due to muscle symptoms or other adverse effects, use the maximally tolerated dose 1, 3

Step 2: Add Ezetimibe First

  • Ezetimibe 10 mg daily must be added before considering Repatha 1, 4, 2
  • This provides an additional 15-25% LDL-C reduction beyond statin monotherapy 1, 4, 2
  • Reassess LDL-C levels 4-12 weeks after adding ezetimibe 4
  • The 2018 ACC/AHA guidelines give ezetimibe a Class IIa recommendation for patients with clinical ASCVD on maximally tolerated statin therapy with LDL-C ≥70 mg/dL 2

Step 3: Consider Bempedoic Acid (Optional)

  • If LDL-C remains above target after statin plus ezetimibe, bempedoic acid 180 mg daily can be added before proceeding to PCSK9 inhibitors 2
  • This yields an additional 15-25% LDL-C reduction and is particularly useful in statin-intolerant patients 2

Specific Criteria for Repatha Initiation

Only proceed to Repatha after completing Steps 1-2 above when the following criteria are met:

Primary Indication

  • LDL-C remains ≥70 mg/dL despite maximally tolerated statin therapy plus ezetimibe 1, 2, 5
  • Patient has established ASCVD (prior MI, stroke, symptomatic peripheral arterial disease) 5

Very High-Risk Features (Target LDL-C <55 mg/dL)

  • Recent myocardial infarction (within 2 years) 1
  • Multivessel coronary disease 1
  • Diabetes with established ASCVD 1, 4
  • Recurrent atherothrombotic events despite optimal therapy 2

High-Risk Features (Target LDL-C <70 mg/dL)

  • Established ASCVD without recent events 1
  • Diabetes with multiple cardiovascular risk factors 4

Severe Hypercholesterolemia

  • LDL-C ≥190 mg/dL with <50% reduction or LDL-C ≥100 mg/dL despite maximal statin plus ezetimibe therapy 2
  • Homozygous familial hypercholesterolemia 5

FDA-Approved Indications for Repatha

Per the FDA label, Repatha is indicated for: 5

  • Adults with established cardiovascular disease and LDL-C ≥70 mg/dL on maximally tolerated statin therapy
  • Adults and pediatric patients ≥10 years with homozygous familial hypercholesterolemia requiring additional LDL-C lowering

Expected Efficacy

  • Repatha reduces LDL-C by approximately 50-60% when added to statin therapy 1, 2
  • In the FOURIER trial, Repatha significantly reduced major cardiovascular events (cardiovascular death, MI, stroke, coronary revascularization, hospitalization for unstable angina) with a hazard ratio of 0.85 (95% CI: 0.79-0.92, p<0.0001) 5
  • The key secondary endpoint (cardiovascular death, MI, or stroke) was also significantly reduced (p<0.0001) 5

Dosing Regimen

  • 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly 5
  • In the FOURIER trial, 86% of patients used the every-2-week regimen 5

Critical Pitfall to Avoid

Do not skip ezetimibe and proceed directly to PCSK9 inhibitors – most patients achieve adequate LDL-C lowering with statin plus ezetimibe, making ezetimibe the cost-effective and evidence-based choice before considering the significantly more expensive PCSK9 inhibitors 4, 2. The ACC/AHA guidelines establish a clear hierarchical approach: maximize statin → add ezetimibe → consider PCSK9 inhibitor only if LDL-C remains ≥70 mg/dL 4.

Background Therapy Requirements

  • Most patients in the FOURIER trial were on high-intensity (69%) or moderate-intensity (30%) statin therapy, with only 5% also taking ezetimibe at baseline 5
  • Ensure patients are also on appropriate cardiovascular medications including antiplatelet agents, beta blockers, ACE inhibitors, or ARBs as indicated 5

References

1
Guideline

Management of Elevated LDL in High-Risk Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

2
Guideline

Ezetimibe as First‑Line Add‑On Therapy for Patients on Maximally Tolerated Statins

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Management of Elevated LDL in Type 2 Diabetes on Maximum Statin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the effect of combining 40mg of rosuvastatin (statin) and ezetimibe (ezetimibe) 10mg daily on low-density lipoprotein cholesterol (LDL-C) levels?
Patient has difficulty tolerating atorvastatin and ezetimibe for hypercholesterolemia; can she try low-dose rosuvastatin?
What is the preferred combination of Ezetimibe with either Simvastatin, Rosuvastatin, or Atorvastatin for cholesterol-lowering therapy?
Can I add ezetimibe to rosuvastatin (Crestor) 10mg to help lower low-density lipoprotein (LDL) cholesterol levels if increasing the rosuvastatin dose to 20mg is not covered by insurance?
Can the rosuvastatin/ezetimibe combination tablet be crushed?
In a reproductive‑age woman presenting with acute severe lower abdominal or pelvic pain, nausea, and a possible adnexal mass, can a pelvic ultrasound with Doppler flow assessment reliably rule out ovarian torsion?
What medications commonly used in dementia patients can cause pinpoint (constricted) pupils?
Is there utility in ordering lipoprotein(a) (Lp(a)) and apolipoprotein B (ApoB)?
When should homologous recombination deficiency (HRD) testing be performed in patients with newly diagnosed high‑grade serous or endometrioid ovarian carcinoma, including timing relative to surgery, pathology review, first‑line platinum‑taxane chemotherapy, and at recurrence before PARP‑inhibitor maintenance?
What are the recommended anticoagulation regimens and duration for provoked versus unprovoked pulmonary embolism?
What is the recommended management for a 49‑year‑old man with elevated total cholesterol, elevated low‑density lipoprotein cholesterol, elevated non‑high‑density lipoprotein cholesterol, and moderately elevated triglycerides?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.